Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead as generic competition and litigation liabilities bed in. Pharma ...

Seven years ago, two events set forth a domino effect culminating in Bayer leaders having a potential “tough decision” of whether or not the company will continue to manufacture its legacy herbicide ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s crop science division. What has them bullish? First, Bayer is optimistic the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...